As of Tuesday, March 24, Fennec Pharmaceuticals Inc.’s FENC share price has dipped by 11.95%, which has investors questioning ...

The latest price target for Fennec Pharmaceuticals (NASDAQ:FENC) was reported by HC Wainwright & Co. on August 21, 2025. The analyst firm set a price target for $13.00 expecting FENC to rise to within ...

Detailed price information for Fennec Pharmaceuticals Inc (FENC-Q) from The Globe and Mail including charting and trades.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) reported fourth-quarter results on Tuesday that came in below analyst forecasts, ...

Fennec Pharmaceuticals (FENC) (the Company), is a small cap, commercial-stage biotech company with a single drug, PEDMARK®. PEDMARK is a unique formulation of sodium thiosulfate specifically developed ...

Stephens initiated coverage of Fennec (FENC) with an Overweight rating and $15 price target The firm is adding to its Biotechnology research coverage with a focus on targeted protein degradation, or ...

The average one-year price target for Fennec Pharmaceuticals (TSX:FRX) has been revised to $21.57 / share. This is an increase of 10.41% from the prior estimate of $19.53 dated November 16, 2025. The ...

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Fennec Pharmaceuticals (FENC – Research Report). The company’s shares closed last Friday at $5.76.

Maxim Group analyst Jason McCarthy has maintained their bullish stance on FENC stock, giving a Buy rating on March 22. Jason McCarthy has given his Buy rating due to a combination of factors including ...

Detailed price information for Fennec Pharmaceuticals Inc (FENC-Q) from The Globe and Mail including charting and trades.